Troxacitabine Synthesis via Segmentation and Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing synthesis method for troxacitabine is time-consuming and complex, involving multiple reaction systems and intermediate products, making it unsuitable for commercial production and scaling up.
Innovation Solution
A two-step synthesis method for troxacitabine is developed, involving a simplified chemical reaction process with specific reagents and purification steps, along with crystallization methods to produce stable crystal forms suitable for commercial production and pharmaceutical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the existing synthesis method using dyhydroxy L-menthyl acetate is used, then troxacitabine can be produced, but the synthesis procedure becomes time-consuming and complicated with multiple reaction systems and intermediate products
Solution Approach 1:
The synthesis method is divided into two distinct steps: Step 1 involves condensation reaction of cytosine with formaldehyde and ammonium acetate to form intermediate (2S,4S)-2-(hydroxymethyl)-1,3-dioxol-4-yl)pyrimidine-2(1H)-one; Step 2 involves conversion of the intermediate to troxacitabine using trimethylsilyl iodide and hexamethyldisilazane. This segmentation allows each step to be optimized independently and simplifies the overall process compared to the existing multi-step method
Solution Approach 2:
Multiple reaction operations are combined into fewer steps. The condensation and cyclization reactions are performed in one pot to generate the dioxolyl-pyrimidone intermediate, which then undergoes silylation and substitution in a second combined step to yield the final product. This merging eliminates the need for separate halogenation and coupling reactions required in the existing method
2Productivity
If the existing synthesis method with multiple separations is used, then intermediate products can be isolated, but frequent changing of reaction container is required making it unsuitable for scaling up
Solution Approach 1:
The synthesis is organized into two main reaction segments that can be performed in sequence in the same reaction vessel. The first segment produces the intermediate which remains in solution, and the second segment converts it to the final product without requiring isolation. This segmentation strategy maintains productivity while minimizing container operations
Solution Approach 2:
The intermediate (2S,4S)-2-(hydroxymethyl)-1,3-dioxol-4-yl)pyrimidine-2(1H)-one acts as a stable species that can be generated in one pot and directly converted to the final product. This intermediary compound allows the two-step synthesis to proceed without requiring isolation of intermediates, thereby improving scalability while maintaining product quality
3Stability of the object's composition
If multiple crystal forms of troxacitabine are identified, then stable crystal form C can be selected for room temperature storage, but additional crystallization studies are required
Solution Approach 1:
Different crystal forms were obtained by changing crystallization parameters such as solvent type (acetone, isopropyl alcohol, water), temperature (room temperature, 4°C, -20°C), and evaporation conditions. Crystal form C was identified as the most stable at room temperature through systematic parameter optimization, balancing the additional study time with the benefit of improved storage stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new method allows for high-purity troxacitabine production, enabling scalable commercial production and identifying stable crystal forms, particularly crystal form C, which is stable at room temperature and humidity, suitable for solid dosage forms and effective in treating tumors and viral infections.
Implementation Method 1
dyhydroxy L-menthyl acetate is used as starting materials to condensation react with glycolic aldehyde
Implementation Method 2
derive halides after its hydroxy being halogeneated
Implementation Method 3
Halides couple with cytosine to derive a conjugate
Implementation Method 4
conjugate that is reduced to derive troxacitabine
Implementation Method 5
Heat formula III compound to 80° C. using a baking oven, maintain for 10 min and cool down to room temperature
Implementation Method 6
Heat formula III compound to 80° C. using a baking oven
Implementation Method 7
cool down to room temperature
Implementation Method 8
Dissolve formula III compound in water, volatilize in a fume hood with the top open for 3 days
Implementation Method 9
Dissolve formula III compound in water
Implementation Method 10
centrifugate for 3 min at a rate of 10000 rpm
Data Source
AI summary
This invention provides synthesis method, crystallization method, etc. for troxacitabine, and also the crystal form and use of troxacitabine.